The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Professor Juris Meier is Professor of Medicine and Chief Physician of the Department of Internal Medicine, Gastroenterology and Diabetology at the Augusta Hospital in Bochum, Germany. He received his medical degree with honours from the Medical School at Ruhr University Bochum and has performed research fellowships at the Panum Institute at the University of Copenhagen, Denmark and UCLA School of Medicine, California, USA. Professor Meier has received numerous national and international scientific awards, including a Rising Star Lecture from the European Association for the Study of Diabetes and the Werner Creutzfeldt Prize from the German Diabetes Association.
Professor Meier has authored and co-authored over 200 publications in peer-reviewed journals, as well as several book chapters. He currently serves as Associate Editor of Diabetologia and has been a member of the Editorial Board of Diabetes and Regulatory Peptides, in addition to his role as a reviewer for journals including The New England Journal of Medicine, The Lancet, Diabetes Care and the Journal of Clinical Endocrinology & Metabolism. Professor Meier’s research interests include the regulation of insulin secretion in vivo, the physiological actions and therapeutic applications of incretin hormones, and the mechanisms of beta-cell death in patients with diabetes.